<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Pasithea Therapeutics Corporation (KTTA) 周一表示，已任命 Kartik Krishnan 为首席医学官，任职时间从 5 月 1 日起生效。</p>
<p>Krishnan 在临床开发、药物警戒、临床运营等方面拥有超过 20 年的经验。</p>
<p>在加入 Pasithea 之前，Krishnan 曾担任 OncoNano Medicines 的首席执行官，该公司是一家开发抗癌资产的私营公司。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

KTTAW

KTTA

标普全球医疗股指数 ETF - iShares

<p>Pasithea Therapeutics Corporation (KTTA) 已任命 Kartik Krishnan 为首席医学官，任职时间从 5 月 1 日开始。Krishnan 拥有超过 20 年的临床开发及相关领域的经验，曾担任 OncoNano Medicines 的首席执行官，该公司专注于抗癌资产</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Pasithea Therapeutics Corporation (KTTA) said on Monday that it has appointed Kartik Krishnan as chief medical officer with effect from May 1.</p>
<div class="lb-trans"><p>Pasithea Therapeutics Corporation (KTTA) 周一表示，已任命 Kartik Krishnan 为首席医学官，任职时间从 5 月 1 日起生效。</p>
</div><p>Krishnan has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, and others.</p>
<div class="lb-trans"><p>Krishnan 在临床开发、药物警戒、临床运营等方面拥有超过 20 年的经验。</p>
</div><p>Prior to joining Pasithea, Krishnan was chief executive officer at OncoNano Medicines, a privately held company developing anti-cancer assets.</p>
<div class="lb-trans"><p>在加入 Pasithea 之前，Krishnan 曾担任 OncoNano Medicines 的首席执行官，该公司是一家开发抗癌资产的私营公司。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Pasithea Therapeutics Appoints Kartik Krishnan As CMO

rttnews

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM)

Pasithea Therapeutics

基因改革 ETF - ARK

医疗业 ETF - SPDR

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

Pasithea Therapeutics 任命 Kartik Krishnan 为首席医疗官（CMO）